Strive Financial Group’s Ironwood Pharmaceuticals IRWD Stock Holding History

Strive Financial Group’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$11.9K	Buy	+3,000	New	+$12.5K	﹤0.01%	646

Other funds holding IRWD

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Strive Financial Group's IRWD Position: Q3 2026 in Review

Strive Financial Group opened a new position in Ironwood Pharmaceuticals (IRWD) in Q3 2026: 3,000 shares worth $11.9K. The stake represents ﹤0.01% of the portfolio and ranks #646 among its holdings.

176 funds tracked by Wall St. Rank hold IRWD as of Q3 2026.

Strive Financial Group held 3,000 shares of Ironwood Pharmaceuticals worth $11.9K as of Q3 2026.
Ironwood Pharmaceuticals was a new Strive Financial Group position in Q3 2026.
Ironwood Pharmaceuticals made up ﹤0.01% of Strive Financial Group's portfolio in Q3 2026, its #646 holding.
176 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2026.

Based on Strive Financial Group's 13F filing for Q3 2026, filed 9 Nov 2026.